文献速递认知障碍与痴呆

18F-flortaucipir PET预测阿尔茨海默病神经病理改变的尸检验证

Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.
PubMed 文献 · JAMA Neurol · 2020-01-01

这项诊断研究在28个中心纳入156例临终患者,生前接受18F-flortaucipir PET显像,由5名独立读片者判读,并与尸检免疫组化tau病理比较。结果显示PET预测B3级tau病理的敏感性92.3%–100.0%、特异性52.0%–92.0%,预测高水平AD神经病理改变的敏感性94.7%–100.0%、特异性50.0%–92.3%,验证研究同样达到预设成功标准。

要点

  • 18F-flortaucipir PET可预测尸检B3级tau病理,敏感性高、特异性范围较宽。
  • PET预测高水平AD神经病理改变的敏感性94.7%–100.0%,特异性50.0%–92.3%。
  • 验证研究达到预设成功标准,支持该PET用于AD神经病理诊断。

核心结论

  • 18F-flortaucipir PET可识别AD型tau病理的密度与分布及高水平AD神经病理改变,支持AD的神经病理诊断。

研究设计与样本

  • A16 primary cohort为诊断研究,2015年10月至2018年6月在28个中心纳入156例50岁以上终末期患者,均行18F-flortaucipir PET,扫描由5名独立核医学医师或放射科医师判读。
  • 73例死亡,67例完成有效尸检,3例作为测试病例移出主要队列,主要队列n=64;另收集16例历史尸检病例的补充影像与病理样本。
  • FR01 validation study于2019年3月26日至4月26日由5名新读片者评估原始PET图像并与尸检比较。
  • 成功标准定义为5名读片者中至少3名的敏感性和特异性均高于50%的95%CI下限。

主要发现

  • 64例主要队列患者中34例(53%)为女性、62例(97%)为白人,平均(SD)年龄82.5(9.6)岁;49例(77%)痴呆、1例(2%)轻度认知障碍、14例(22%)认知正常。
  • flortaucipir PET预测B3级tau病理的敏感性92.3%(95%CI,79.7%-97.3%)至100.0%(95%CI,91.0%-100.0%),特异性52.0%(95%CI,33.5%-70.0%)至92.0%(95%CI,75.0%-97.8%)。
  • 预测高水平AD神经病理改变的敏感性94.7%(95%CI,82.7%-98.5%)至100.0%(95%CI,90.8%-100.0%),特异性50.0%(95%CI,32.1%-67.9%)至92.3%(95%CI,75.9%-97.9%)。
  • FR01验证研究达到预设成功标准;合并补充尸检数据与3例测试病例(共82例)后特异性改善、总体准确性相当。
  • 156例入组参与者中14例(9%)发生至少1次治疗中出现的不良事件。

关键数值与推荐

  • 预先设定的成功标准为5名读片者中至少3名的敏感性和特异性均高于50%的95%CI下限。
  • A16主要队列达到预设成功标准,FR01验证研究也达到预设成功标准。

临床怎么用

  • 对于临床怀疑AD相关神经病理改变的患者,18F-flortaucipir PET可用于评估AD型tau病理的密度与分布及高水平AD神经病理改变。
  • 判读时应关注其高敏感性及特异性范围较宽的特点,结合临床与其他生物标志物综合判断。

局限性

  • 主要队列以白人(97%)和痴呆患者(77%)为主,平均年龄82.5岁,外推需谨慎。
  • 特异性范围较宽(最低52.0%),存在假阳性可能。
  • 补充尸检数据与3例测试病例合并分析后特异性改善,提示样本与判读条件对结果有影响。
  • 入组为预期寿命不足6个月的终末期患者,不能代表一般临床人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Positron emission tomography (PET) may increase the diagnostic accuracy and confirm the underlying neuropathologic changes of Alzheimer disease (AD). OBJECTIVE: To determine the accuracy of antemortem [18F]flortaucipir PET images for predicting the presence of AD-type tau pathology at autopsy. DESIGN, SETTING, AND PARTICIPANTS: This diagnostic study (A16 primary cohort) was conducted from October 2015 to June 2018 at 28 study sites (27 in US sites and 1 in Australia). Individuals with a terminal illness who were older than 50 years and had a projected life expectancy of less than 6 months were enrolled. All participants underwent [18F]flortaucipir PET imaging, and scans were interpreted by 5 independent nuclear medicine physicians or radiologists. Supplemental autopsy [18F]flortaucipir images and pathological samples were also collected from 16 historically collected cases. A second study (FR01 validation study) was conducted from March 26 to April 26, 2019, in which 5 new readers assessed the original PET images for comparison to autopsy. MAIN OUTCOMES AND MEASURES: [18F]flortaucipir PET images were visually assessed and compared with immunohistochemical tau pathology. An AD tau pattern of flortaucipir retention was assessed for correspondence with a postmortem B3-level (Braak stage V or VI) pathological pattern of tau accumulation and to the presence of amyloid-β plaques sufficient to meet the criteria for high levels of AD neuropathological change. Success was defined as having at least 3 of the 5 readers above the lower bounds of the 95% CI for both sensitivity and specificity of 50% or greater. RESULTS: A total of 156 patients were enrolled in the A16 study and underwent [18F]flortaucipir PET imaging. Of these, 73 died during the study, and valid autopsies were performed for 67 of these patients. Three autopsies were evaluated as test cases and removed from the primary cohort (n = 64). Of the 64 primary cohort patients, 34 (53%) were women and 62 (97%) were white; mean (SD) age was 82.5 (9.6) years; and 49 (77%) had dementia, 1 (2%) had mild cognitive impairment, and 14 (22%) had normal cognition. Prespecified success criteria were met for the A16 primary cohort. The flortaucipir PET scans predicted a B3 level of tau pathology, with sensitivity ranging from 92.3% (95% CI, 79.7%-97.3%) to 100.0% (95% CI, 91.0%-100.0%) and specificity ranging from 52.0% (95% CI, 33.5%-70.0%) to 92.0% (95% CI, 75.0%-97.8%). A high level of AD neuropathological change was predicted with sensitivity of 94.7% (95% CI, 82.7%-98.5%) to 100.0% (95% CI, 90.8%-100.0%) and specificity of 50.0% (95% CI, 32.1%-67.9%) to 92.3% (95% CI, 75.9%-97.9%). The FR01 validation study also met prespecified success criteria. Addition of the supplemental autopsy data set and 3 test cases, which comprised a total of 82 patients and autopsies for both the A16 and FR01 studies, resulted in improved specificity and comparable overall accuracy. Among the 156 enrolled participants, 14 (9%) experienced at least 1 treatment-emergent adverse event. CONCLUSIONS AND RELEVANCE: This study's findings suggest that PET imaging with [18F]flortaucipir could be used to identify the density and distribution of AD-type tau pathology and the presence of high levels of AD neuropathological change, supporting a neuropathological diagnosis of AD.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Fleisher AS, Pontecorvo MJ, Devous MD, et al. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020. PMID: 32338734. doi:10.1001/jamaneurol.2020.0528

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。